76 related articles for article (PubMed ID: 16912172)
1. Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density.
Pozner-Moulis S; Pappas DJ; Rimm DL
Cancer Res; 2006 Aug; 66(16):7976-82. PubMed ID: 16912172
[TBL] [Abstract][Full Text] [Related]
2. The function, proteolytic processing, and histopathology of Met in cancer.
Hanna JA; Bordeaux J; Rimm DL; Agarwal S
Adv Cancer Res; 2009; 103():1-23. PubMed ID: 19854350
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte growth factor differently influences Met-E-cadherin phosphorylation and downstream signaling pathway in two models of breast cells.
Matteucci E; Ridolfi E; Desiderio MA
Cell Mol Life Sci; 2006 Sep; 63(17):2016-26. PubMed ID: 16909210
[TBL] [Abstract][Full Text] [Related]
4. The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor.
Komada M; Kitamura N
Oncogene; 1993 Sep; 8(9):2381-90. PubMed ID: 7689722
[TBL] [Abstract][Full Text] [Related]
5. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes.
Monga SP; Mars WM; Pediaditakis P; Bell A; Mulé K; Bowen WC; Wang X; Zarnegar R; Michalopoulos GK
Cancer Res; 2002 Apr; 62(7):2064-71. PubMed ID: 11929826
[TBL] [Abstract][Full Text] [Related]
7. Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells.
Seiden-Long I; Navab R; Shih W; Li M; Chow J; Zhu CQ; Radulovich N; Saucier C; Tsao MS
Carcinogenesis; 2008 Mar; 29(3):647-55. PubMed ID: 18192688
[TBL] [Abstract][Full Text] [Related]
8. Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells.
Matteucci E; Bendinelli P; Desiderio MA
Carcinogenesis; 2009 Jun; 30(6):937-45. PubMed ID: 19357348
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the N-terminal unique domain of Chk tyrosine kinase in Chk-induced tyrosine phosphorylation in the nucleus.
Nakayama Y; Kawana A; Igarashi A; Yamaguchi N
Exp Cell Res; 2006 Jul; 312(12):2252-63. PubMed ID: 16707123
[TBL] [Abstract][Full Text] [Related]
10. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma.
Kongkham PN; Northcott PA; Ra YS; Nakahara Y; Mainprize TG; Croul SE; Smith CA; Taylor MD; Rutka JT
Cancer Res; 2008 Dec; 68(23):9945-53. PubMed ID: 19047176
[TBL] [Abstract][Full Text] [Related]
11. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival.
Shinomiya N; Gao CF; Xie Q; Gustafson M; Waters DJ; Zhang YW; Vande Woude GF
Cancer Res; 2004 Nov; 64(21):7962-70. PubMed ID: 15520203
[TBL] [Abstract][Full Text] [Related]
12. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells.
Guo Y; Zi X; Koontz Z; Kim A; Xie J; Gorlick R; Holcombe RF; Hoang BH
J Orthop Res; 2007 Jul; 25(7):964-71. PubMed ID: 17318900
[TBL] [Abstract][Full Text] [Related]
13. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Kang JY; Dolled-Filhart M; Ocal IT; Singh B; Lin CY; Dickson RB; Rimm DL; Camp RL
Cancer Res; 2003 Mar; 63(5):1101-5. PubMed ID: 12615728
[TBL] [Abstract][Full Text] [Related]
14. Met receptor signaling: a key effector in esophageal adenocarcinoma.
Anderson MR; Harrison R; Atherfold PA; Campbell MJ; Darnton SJ; Obszynska J; Jankowski JA
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5936-43. PubMed ID: 17062664
[TBL] [Abstract][Full Text] [Related]
15. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
16. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor.
Zhang YW; Su Y; Lanning N; Gustafson M; Shinomiya N; Zhao P; Cao B; Tsarfaty G; Wang LM; Hay R; Vande Woude GF
Oncogene; 2005 Jan; 24(1):101-6. PubMed ID: 15531925
[TBL] [Abstract][Full Text] [Related]
17. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.
Okuda K; Sasaki H; Yukiue H; Yano M; Fujii Y
Cancer Sci; 2008 Nov; 99(11):2280-5. PubMed ID: 19037978
[TBL] [Abstract][Full Text] [Related]
18. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
19. Expression of the met/hepatocyte growth factor/scatter factor receptor and its ligand during differentiation of murine P19 embryonal carcinoma cells.
Yang XM; Park M
Dev Biol; 1993 Jun; 157(2):308-20. PubMed ID: 8388815
[TBL] [Abstract][Full Text] [Related]
20. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells.
Bigelow RL; Cardelli JA
Oncogene; 2006 Mar; 25(13):1922-30. PubMed ID: 16449979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
